1450 Results
Sort By:
Published on June 5, 2017
The more diverse the digestive tract bacteria, the slower the progression of metastatic melanoma in patients treated with immunotherapy, researchers at The University of Texas MD Anderson Cancer Center reported today. At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the researchers presented results from a…
Published on May 23, 2017
Seattle Children’s said today it has launched the first clinical trial designed to better understand how the immune system drives both inflammatory bowel disease (IBD) in pediatric autoimmunity patients and graft-versus host disease (GVHD) in pediatric bone marrow transplant patients. The PREDICT (Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy…
Published on May 1, 2017
Epic Sciences said it will use proceeds from a recently-completed $40 million Series D financing to accelerate development of its liquid biopsy cancer tests, and enhance its platform technology for identifying and characterizing rare cells, including circulating tumor cells (CTCs). Epic’s tests are designed to predict drug response in cancer.…
Published on April 14, 2017
NantOmics, a molecular diagnostics developer and part of the NantWorks umbrella of nine companies founded by Patrick Soon-Shiong, M.D., has acquired Genos, a Complete Genomics spinout focusing on personal genetic discovery and research, for an undisclosed price. Genos offers whole-exome DNA sequencing through a $499 saliva kit that the company…
Published on April 12, 2017
In today’s drug development landscape, where targeted therapies are increasingly common, partnerships between pharmaceutical and diagnostics companies for the development of a companion diagnostic are on the rise. Clinical OMICs Editor in Chief Chris Anderson recently spoke with David Parker, Ph.D., senior vice president, diagnostics solutions, at Precision for Medicine about…
Published on April 4, 2017
Whitehead Institute investigators have identified a gene overexpressed in a subset of early-stage breast cancers called SMARCE1, that they say show which cancers are likely to become aggressively invasive, a finding that for the first time makes it possible to distinguish poorly invasive tumors for those that will likely spread…
Published on March 24, 2017
In the fight against cancer, scientists and clinicians have looked toward novel approaches that provide a more comprehensive understanding of the molecular mechanisms that drive the disease—all with the hope of uncovering new therapies that afford many patients a better quality of care. To that end, in August of 2015, the…
Published on March 22, 2017
Liquid biopsies in oncology initially focused on detecting and analyzing the numbers and types of circulating tumor cells (CTCs) in the blood, but more recently many researchers have come to include analysis of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA). cfDNA testing was first used in the United States…
Published on March 21, 2017
Like many hospitals affiliated with medical schools and medical research, doctors at Vidant Health in Eastern North Carolina had been dabbling in the use of liquid biopsies, to both ease the burden of invasive tissue biopsy procedures, and to learn about how well it could provide relevant information to guide…
Published on March 21, 2017
In 1928, H.B. Reese, a former dairy farmer working as a shipping foreman for Milton S. Hershey, became inspired and decided to strike out on his own, opening The Harry Burnett Reese Candy Company in the basement of his house. Mr. Reese created one the most popular and beloved confectionery treats—Reese’s…
Published on February 21, 2017
Georgia State University (GSU) researchers have just published new results showing that high levels of a certain biomarker is linked to poor prognosis in African-American patients with triple-negative breast cancer. Researchers are concerned that the dire outcome of this group could indicate that high-risk, African-American breast cancer patients are not…
Published on February 21, 2017
Interpace Diagnostics said today it has launched a research collaboration with Viatar CTC Solutions focused on detecting and characterizing early cancer in liquid biopsies. The collaboration—whose value was not disclosed—will apply Viatar's novel circulating tumor cell collection technology in combination with Interpace’s marketed PancraGEN™ assay, designed to help assess indeterminate…
Published on February 3, 2017
A pilot project designed to advance precision medicine for people with cancer in Canada was launched today by a research institution and two of the country’s leading cancer centers. The Terry Fox Research Institute (TFRI), the Princess Margaret Cancer Centre in Toronto, and the BC Cancer Agency in Vancouver, will…
Published on February 3, 2017
The National Cancer Institute (NCI) recently completed a material transfer agreement with German autoantibody screening and diagnostic developer Protagen AG, for the use of Protagen’s SeroTag immune system profile technology. The collaboration will be led by Jeffrey Schlom, Ph.D., chief of the laboratory of tumor Immunology and biology at the…
Published on January 24, 2017
Scientists at The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that should aid in the subclassification of the disease, and may help target therapies that are most appropriate for each patient. The new study, published recently in Nature through an article…